Parabilis Medicines, Inc. (PBLS)
30.37
+1.84
(+6.45%)
USD |
NASDAQ |
Nov 09, 16:00
29.77
-0.60
(-1.98%)
After-Hours: 20:00
Parabilis Medicines Shareholders Equity (Quarterly) : 1.048B for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.048B |
| Date | Value |
|---|---|
| March 31, 2026 | 244.22M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.529B |
| Anixa Biosciences, Inc. | 14.47M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.175B |
| Total Liabilities (Quarterly) | 127.53M |
| Debt to Equity Ratio | 0.0453 |
| Current Ratio | 17.91 |
| Net Debt Paydown Yield | -0.22% |